|
TOB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.03319583391703E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.84859946531446E-11 |
| Normal-vs-Stage2 |
3.45220000363966E-08 |
| Normal-vs-Stage3 |
6.7079675147852E-12 |
| Normal-vs-Stage4 |
1.71451741692863E-12 |
| Stage1-vs-Stage2 |
3.784400E-01 |
| Stage1-vs-Stage3 |
2.103000E-01 |
| Stage1-vs-Stage4 |
2.1610999999977E-05 |
| Stage2-vs-Stage3 |
8.552100E-02 |
| Stage2-vs-Stage4 |
3.742300E-03 |
| Stage3-vs-Stage4 |
4.101700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.06960029511561E-11 |
| Normal-vs-AfricanAmerican |
9.38860100774264E-11 |
| Normal-vs-Asian |
6.38034070021831E-12 |
| Caucasian-vs-AfricanAmerican |
4.583400E-01 |
| Caucasian-vs-Asian |
1.568450E-01 |
| AfricanAmerican-vs-Asian |
7.617800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.18531875823192E-12 |
| Normal-vs-Female |
5.26489962737742E-11 |
| Male-vs-Female |
5.540100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.78479461712777E-11 |
| Normal-vs-Age(41-60Yrs) |
3.54000162516854E-11 |
| Normal-vs-Age(61-80Yrs) |
3.66360275450006E-11 |
| Normal-vs-Age(81-100Yrs) |
2.176300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.508600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.144600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.071000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.943000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.390200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.521800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.800510E-03 |
| Classical-VS-Follicular |
3.503800E-01 |
| Classical-VS-Other |
6.071600E-01 |
| Classical-VS-Normal |
3.99790200944494E-11 |
| Tall-VS-Follicular |
1.105980E-02 |
| Tall-VS-Other |
3.842200E-01 |
| Tall-VS-Normal |
1.85718107559296E-12 |
| Follicular-VS-Other |
1.982850E-01 |
| Follicular-VS-Normal |
9.56229995185964E-09 |
| Other-VS-Normal |
9.40879996136346E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.35319558178549E-11 |
| Normal-vs-N1 |
1.91102689228728E-12 |
| N0-vs-N1 |
2.519400E-03 |
|
|
